ACOR | Acorda Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6116 - 0.8500
52 Week Range	0.6116 - 24.20
Beta	1.09
Implied Volatility	387.33%
IV Rank	66.23%
Day's Volume	321,668
Average Volume	125,680
Shares Outstanding	1,242,100
Market Cap	821,028
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2006-02-10

Valuation
Profitability
Growth
Health
P/E Ratio	0.00
Forward P/E Ratio	N/A
EPS	-203.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	102
Country	USA
Website	ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

ACOR's peers: AKAN, BFRI, CPHI, HUGE, RMTI, SNOA, SXTC

*Chart delayed

Analyzing fundamentals for ACOR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ACOR Fundamentals page.

Watching at ACOR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ACOR Technicals page.